API | tideglusib

tideglusib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Tideglusib is a potent and irreversible small molecule glycogen synthase kinase 3 (GSK-3) inhibitor. ^Wikipedia

Chemistry

SMILES: O=c1sn(-c2cccc3ccccc23)c(=O)n1Cc1ccccc1
InChIKey: PMJIHLSCWIDGMD-UHFFFAOYSA-N
Mol. Mass: 334.4
ALogP: 3.26 Partition coefficient
ChEMBL Molecule:
tideglusib

More Chemistry

Pharmacology

Mechanism of Action:
- Glycogen synthase kinase-3 beta (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

np031112 | np 031112 | np-031112 | np-12 | np-12 compound | tideglusib

Organizations (16)

Research & Development (16)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Alzheimer Disease (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Arrhythmogenic Right Ventricular Dysplasia (Phase 2)

Autism Spectrum Disorder (Phase 2)

Myotonic Dystrophy (Phase 2/Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial Organizations: 16

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue